Moderna Inc logo

Moderna Inc MRNA

Market Closed
14 Jun, 20:00
140. 03
After Hours
140. 00
-0.03 -0.02%
38.83B Market Cap
- P/E Ratio
0% Div Yield
3,597,100 Volume
-13.23 Eps
$ 145.23
Previous Close
Day Range
138.17 145.74
Year Range
62.55 170.47

MRNA Chart

Moderna Inc Profile

Biotechnology Industry
Healthcare Sector
Mr. Stephane Bancel CEO
NASDAQ (NGS) Exchange
US60770K1079 ISIN
US Country
5,600 Employees
- Last Dividend
- Last Split
7 Dec 2018 IPO Date


Moderna, Inc., is a pioneering biotechnology firm founded in 2010, with its headquarters located in Cambridge, Massachusetts. Initially known as Moderna Therapeutics, Inc., the company rebranded to Moderna, Inc. in August 2018. It specializes in leveraging messenger RNA (mRNA) technology to develop, discover, and commercialize therapeutics and vaccines for a wide array of diseases. These diseases range from infectious diseases, immuno-oncology, rare diseases, to autoimmune and cardiovascular diseases. Moderna's operations span across the United States, Europe, and globally. The company has established strategic alliances and collaborations with notable entities in the biotech and pharmaceutical industry, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., and The Bill & Melinda Gates Foundation, among others.

Products and Services

  • Respiratory Vaccines

    Moderna's respiratory portfolio includes vaccines against COVID-19, influenza, and respiratory syncytial virus. The company utilizes its mRNA technology to develop vaccines like Spikevax, as well as its hMPV/PIV3 vaccine candidates, targeting multiple respiratory pathogens.

  • Latent Vaccines

    The latent vaccines developed by Moderna target a variety of viruses such as the cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and the human immunodeficiency virus. These vaccines aim to provide immunity against viruses that remain dormant in the body and can cause disease upon reactivation.

  • Public Health Vaccines

    Moderna's public health vaccines include projects against diseases like Zika, Nipah, and Mpox. These vaccines are part of Moderna's commitment to addressing emerging public health threats and pandemics with swift vaccine development.

  • Infectious Diseases Vaccines

    Vaccines against Lyme disease and norovirus fall under this category. Moderna leverages its mRNA platform to create vaccines designed to protect against widespread and challenging infectious diseases.

  • Systemic Secreted and Cell Surface Therapeutics

    This innovative category includes therapies that are administered systemically to target secreted and cell surface proteins, leveraging mRNA technology for treating various conditions beyond infectious diseases, including potential treatments for autoimmune and cardiovascular diseases.

  • Cancer Vaccines

    Moderna's oncology portfolio includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines. These products represent an extension of mRNA technology into the field of immuno-oncology, targeting the immune system to fight cancer.

  • Intratumoral Immuno-Oncology Products

    These are innovative treatments administered directly into tumors to elicit a more potent and localized immune response against cancer. They form part of Moderna's broader strategy to harness the body's immune system in combating cancer.

  • Rare Disease Intracellular Therapeutics

    Moderna is developing therapies for rare diseases by targeting intracellular mechanisms. These therapeutics are designed to address genetic disorders and diseases with limited treatment options.

  • Inhaled Pulmonary Therapeutics

    The company is also exploring the potential of inhaled therapies for diseases affecting the lungs, utilizing its mRNA technology to create novel treatments for pulmonary conditions.

Contact Information

Address: 200 Technology Square, Cambridge, MA, United States, 02139
Phone: 617 714 6500